LSTA Stock Overview
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lisata Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.84 |
| 52 Week High | US$3.83 |
| 52 Week Low | US$2.05 |
| Beta | 1.22 |
| 11 Month Change | -2.07% |
| 3 Month Change | 3.27% |
| 1 Year Change | 14.06% |
| 33 Year Change | -79.81% |
| 5 Year Change | -92.53% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
Jul 15
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
Mar 22We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
Sep 15Caladrius rallies on approval of merger, name change to Lisata Therapeutics
Sep 14Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01
Aug 04We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
May 02We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate
Jan 05Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth
May 09Caladrius suspends CLBS119 COVID-19 study
Dec 14Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation
Nov 30
Shareholder Returns
| LSTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | 4.0% | 2.0% |
| 1Y | 14.1% | 18.0% | 32.4% |
Return vs Industry: LSTA underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: LSTA underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| LSTA volatility | |
|---|---|
| LSTA Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LSTA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LSTA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 25 | Dave Mazzo | www.lisata.com |
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics, Inc. Fundamentals Summary
| LSTA fundamental statistics | |
|---|---|
| Market cap | US$24.18m |
| Earnings (TTM) | -US$20.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs LSTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LSTA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.74m |
| Earnings | -US$20.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LSTA perform over the long term?
See historical performance and comparison